康众（北京）生物科技有限公司

Cansino (Beijing) Biotech Co., Ltd. is a key subsidiary and research arm of Cansino Biologics, focusing on the development of innovative vaccines for infectious diseases. The company operates a sophisticated adenovirus-based viral vector platform, which was instrumental in the rapid development of the Ad5-nCoV COVID-19 vaccine and the world's first approved Ebola vaccine. Based in the Beijing Economic-Technological Development Area, it manages critical R&D and pilot-scale production activities for the group. Its portfolio addresses high-priority global health threats, including tuberculosis, pneumonia, and shingles, leveraging advanced biotechnology to provide affordable immunization solutions. The company is a central component of Cansino's strategy to address unmet medical needs through strategic collaborations with academic and military research institutions. Its work is vital to the parent organization's global clinical trial and commercialization efforts.